vs
Side-by-side financial comparison of GAIA, INC (GAIA) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
GAIA, INC is the larger business by last-quarter revenue ($25.5M vs $23.0M, roughly 1.1× Intellia Therapeutics, Inc.). GAIA, INC runs the higher net margin — -0.3% vs -416.2%, a 415.9% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 5.8%). GAIA, INC produced more free cash flow last quarter ($76.0K vs $-69.4M). Over the past eight quarters, GAIA, INC's revenue compounded faster (9.4% CAGR vs -10.8%).
Gaia, Inc. is a publicly traded (NASDAQ:GAIA) American media company founded in 1988 by Jirka Rysavy in Louisville, Colorado. It owns and operates Gaia TV, a subscription video on-demand service consisting of original and licensed alternative media documentaries, including those on wellness, spirituality and conspiracy theories.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
GAIA vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.5M | $23.0M |
| Net Profit | $-75.0K | $-95.8M |
| Gross Margin | 87.6% | — |
| Operating Margin | -2.6% | -428.9% |
| Net Margin | -0.3% | -416.2% |
| Revenue YoY | 5.8% | 78.8% |
| Net Profit YoY | 91.7% | 25.7% |
| EPS (diluted) | $-0.02 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.5M | $23.0M | ||
| Q3 25 | $25.0M | $13.8M | ||
| Q2 25 | $24.6M | $14.2M | ||
| Q1 25 | $23.8M | $16.6M | ||
| Q4 24 | $24.1M | $12.9M | ||
| Q3 24 | $22.0M | $9.1M | ||
| Q2 24 | $21.9M | $7.0M | ||
| Q1 24 | $21.3M | $28.9M |
| Q4 25 | $-75.0K | $-95.8M | ||
| Q3 25 | $-1.2M | $-101.3M | ||
| Q2 25 | $-2.0M | $-101.3M | ||
| Q1 25 | $-1.2M | $-114.3M | ||
| Q4 24 | $-907.0K | $-128.9M | ||
| Q3 24 | $-1.2M | $-135.7M | ||
| Q2 24 | $-2.2M | $-147.0M | ||
| Q1 24 | $-971.0K | $-107.4M |
| Q4 25 | 87.6% | — | ||
| Q3 25 | 86.4% | — | ||
| Q2 25 | 86.7% | — | ||
| Q1 25 | 87.7% | — | ||
| Q4 24 | 88.2% | — | ||
| Q3 24 | 86.1% | — | ||
| Q2 24 | 84.5% | — | ||
| Q1 24 | 85.3% | — |
| Q4 25 | -2.6% | -428.9% | ||
| Q3 25 | -5.0% | -808.9% | ||
| Q2 25 | -8.9% | -772.2% | ||
| Q1 25 | -4.3% | -726.6% | ||
| Q4 24 | -7.1% | -1059.9% | ||
| Q3 24 | -5.3% | -1589.0% | ||
| Q2 24 | -9.1% | -1998.6% | ||
| Q1 24 | -4.0% | -394.0% |
| Q4 25 | -0.3% | -416.2% | ||
| Q3 25 | -4.6% | -735.2% | ||
| Q2 25 | -8.3% | -710.8% | ||
| Q1 25 | -5.1% | -687.6% | ||
| Q4 24 | -3.8% | -1001.2% | ||
| Q3 24 | -5.4% | -1489.5% | ||
| Q2 24 | -9.9% | -2112.6% | ||
| Q1 24 | -4.6% | -371.3% |
| Q4 25 | $-0.02 | $-0.81 | ||
| Q3 25 | $-0.05 | $-0.92 | ||
| Q2 25 | $-0.07 | $-0.98 | ||
| Q1 25 | $-0.04 | $-1.10 | ||
| Q4 24 | $-0.03 | $-1.27 | ||
| Q3 24 | $-0.05 | $-1.34 | ||
| Q2 24 | $-0.09 | $-1.52 | ||
| Q1 24 | $-0.05 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $87.9M | $671.4M |
| Total Assets | $154.6M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | $449.9M | ||
| Q3 25 | $14.2M | $511.0M | ||
| Q2 25 | $13.9M | $459.7M | ||
| Q1 25 | $13.1M | $503.7M | ||
| Q4 24 | $5.9M | $601.5M | ||
| Q3 24 | $4.4M | $658.1M | ||
| Q2 24 | $5.5M | $691.1M | ||
| Q1 24 | $8.6M | $791.3M |
| Q4 25 | $87.9M | $671.4M | ||
| Q3 25 | $86.3M | $748.4M | ||
| Q2 25 | $85.7M | $715.3M | ||
| Q1 25 | $87.0M | $779.9M | ||
| Q4 24 | $80.7M | $872.0M | ||
| Q3 24 | $81.2M | $962.6M | ||
| Q2 24 | $82.1M | $971.1M | ||
| Q1 24 | $84.8M | $1.0B |
| Q4 25 | $154.6M | $842.1M | ||
| Q3 25 | $151.1M | $925.3M | ||
| Q2 25 | $147.0M | $898.9M | ||
| Q1 25 | $148.5M | $986.2M | ||
| Q4 24 | $141.2M | $1.2B | ||
| Q3 24 | $139.6M | $1.2B | ||
| Q2 24 | $142.1M | $1.2B | ||
| Q1 24 | $133.8M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-69.3M |
| Free Cash FlowOCF − Capex | $76.0K | $-69.4M |
| FCF MarginFCF / Revenue | 0.3% | -301.6% |
| Capex IntensityCapex / Revenue | 6.6% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.0K | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-69.3M | ||
| Q3 25 | $326.0K | $-76.9M | ||
| Q2 25 | $2.3M | $-99.6M | ||
| Q1 25 | $1.3M | $-148.9M | ||
| Q4 24 | $2.7M | $-85.2M | ||
| Q3 24 | $409.0K | $-84.8M | ||
| Q2 24 | $-2.1M | $-58.2M | ||
| Q1 24 | $5.9M | $-120.7M |
| Q4 25 | $76.0K | $-69.4M | ||
| Q3 25 | $-1.6M | $-76.9M | ||
| Q2 25 | $880.0K | $-99.9M | ||
| Q1 25 | $268.0K | $-149.7M | ||
| Q4 24 | $1.6M | $-86.2M | ||
| Q3 24 | $-952.0K | $-86.1M | ||
| Q2 24 | $-3.5M | $-59.2M | ||
| Q1 24 | $4.9M | $-123.2M |
| Q4 25 | 0.3% | -301.6% | ||
| Q3 25 | -6.4% | -558.2% | ||
| Q2 25 | 3.6% | -701.0% | ||
| Q1 25 | 1.1% | -900.1% | ||
| Q4 24 | 6.5% | -669.4% | ||
| Q3 24 | -4.3% | -945.2% | ||
| Q2 24 | -16.1% | -850.9% | ||
| Q1 24 | 22.8% | -425.7% |
| Q4 25 | 6.6% | 0.5% | ||
| Q3 25 | 7.7% | 0.2% | ||
| Q2 25 | 5.7% | 1.7% | ||
| Q1 25 | 4.3% | 4.4% | ||
| Q4 24 | 4.6% | 7.6% | ||
| Q3 24 | 6.2% | 14.0% | ||
| Q2 24 | 6.6% | 14.5% | ||
| Q1 24 | 5.0% | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GAIA
| US | $16.7M | 65% |
| Non Us | $8.8M | 35% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
